Hoth Therapeutics (NASDAQ:HOTH) Given “Buy” Rating at D. Boral Capital

Hoth Therapeutics (NASDAQ:HOTH)‘s stock had its “buy” rating reiterated by stock analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $5.00 price objective on the stock. D. Boral Capital’s target price points to a potential upside of 362.96% from the company’s current price.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of Hoth Therapeutics in a research note on Thursday, January 23rd.

Hoth Therapeutics Trading Down 6.9 %

NASDAQ HOTH opened at $1.08 on Tuesday. The business has a fifty day simple moving average of $1.13 and a 200 day simple moving average of $0.94. Hoth Therapeutics has a 12 month low of $0.58 and a 12 month high of $3.80. The firm has a market capitalization of $7.45 million, a P/E ratio of -0.82 and a beta of 0.80.

Hoth Therapeutics (NASDAQ:HOTH) last announced its earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.01). As a group, sell-side analysts predict that Hoth Therapeutics will post -1.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC purchased a new stake in shares of Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned 0.47% of Hoth Therapeutics as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.